-transparent.png){kind=logo}
The 2-hydroxylation of desmethylimipramine (DMI) was studied in 14 healthy subjects previously phenotyped with respect to debrisoquin hydroxylation. After a single oral dose (25 mg), slow hydroxylators of debrisoquin had significantly lower total and metabolic clearances and longer plasma half-lives of DMI and excreted less 2-hydroxydesmethylimipramine than did rapid hydroxylators. These findings strengthen the hypothesis that the hydroxylations of debrisoquin and DMI may be under common enzymatic control.
Related Publications
E Spina, and
E Steiner, and
O Ericsson, and
F Sjöqvist
September 1987,
Clinical pharmacology and therapeutics,
E Spina, and
E Steiner, and
O Ericsson, and
F Sjöqvist
March 1991,
Clinical pharmacology and therapeutics,
E Spina, and
E Steiner, and
O Ericsson, and
F Sjöqvist
September 1986,
Orvosi hetilap,
E Spina, and
E Steiner, and
O Ericsson, and
F Sjöqvist
May 1990,
Presse medicale (Paris, France : 1983),
E Spina, and
E Steiner, and
O Ericsson, and
F Sjöqvist
November 1979,
Clinical pharmacology and therapeutics,
E Spina, and
E Steiner, and
O Ericsson, and
F Sjöqvist
October 1988,
Clinical pharmacology and therapeutics,
E Spina, and
E Steiner, and
O Ericsson, and
F Sjöqvist
April 1989,
Clinical pharmacology and therapeutics,
E Spina, and
E Steiner, and
O Ericsson, and
F Sjöqvist
April 1986,
Clinical pharmacology and therapeutics,
E Spina, and
E Steiner, and
O Ericsson, and
F Sjöqvist
April 1989,
Clinical pharmacology and therapeutics,
E Spina, and
E Steiner, and
O Ericsson, and
F Sjöqvist
May 1989,
Clinical pharmacology and therapeutics,
